Organon Reports Positive Phase 3 Results on Roche Perjuta Biosimilar
Express News | Organon & Co: Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta (Pertuzumab) Biosimilar Candidate HLX11
Roivant Sciences And Organon Announce Merger Agreement For Dermavant Sciences; Roivant Publishes Investor Presentation On Transaction
Express News | Organon & Co -on Sept 17, Co & Unit Entered Into Agreement and Plan of Merger by Dermavant Sciences & Roivant Sciences
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) Low P/E